BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1585 related articles for article (PubMed ID: 33989548)

  • 1. Mechanisms and disease consequences of nonalcoholic fatty liver disease.
    Loomba R; Friedman SL; Shulman GI
    Cell; 2021 May; 184(10):2537-2564. PubMed ID: 33989548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
    Wiering L; Subramanian P; Hammerich L
    Cell Mol Gastroenterol Hepatol; 2023; 15(6):1277-1292. PubMed ID: 36828280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis and non-alcoholic fatty liver diseases.
    Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
    World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease.
    Mills PJ; Caussy C; Loomba R
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):741-743. PubMed ID: 30954713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma.
    Alqahtani SA; Chan WK; Yu ML
    Clin Liver Dis; 2023 May; 27(2):211-223. PubMed ID: 37024203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis.
    Mendez-Sanchez N; Cruz-Ramon VC; Ramirez-Perez OL; Hwang JP; Barranco-Fragoso B; Cordova-Gallardo J
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
    Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
    Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of Non-alcoholic Fatty Liver Disease in North America.
    Arshad T; Golabi P; Henry L; Younossi ZM
    Curr Pharm Des; 2020; 26(10):993-997. PubMed ID: 32124690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis.
    Rui L; Lin JD
    Annu Rev Nutr; 2022 Aug; 42():91-113. PubMed ID: 35584814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease.
    Asgharpour A; Sanyal AJ
    Methods Mol Biol; 2022; 2455():19-30. PubMed ID: 35212982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of liver biopsy in nonalcoholic fatty liver disease.
    Nalbantoglu IL; Brunt EM
    World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semi-Quantitative Ultrasonographic Evaluation of NAFLD.
    Ballestri S; Tana C; Di Girolamo M; Fontana MC; Capitelli M; Lonardo A; Cioni G
    Curr Pharm Des; 2020; 26(32):3915-3927. PubMed ID: 32303161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
    Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.